Source:http://linkedlifedata.com/resource/pubmed/id/18782260
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2008-9-10
|
| pubmed:abstractText |
Human immunodeficiency virus (HIV) infection is a risk factor for thrombotic microangiopathy (TMA). We sought whether a severe deficiency in ADAMTS13, the enzyme specifically involved in the cleavage of von Willebrand factor, was associated with specific presenting features and outcome in HIV-associated TMA. In this prospective, multicentre, case-control study, 29 patients of 236 in the French Network on TMA had an HIV-associated TMA. Seventeen patients with severe ADAMTS13 deficiency (ADAMTS13 <5% HIV(+) group) were compared to 12 patients with a detectable ADAMTS13 activity (ADAMTS13 >or=5% HIV(+) group). HIV(+) patients were also compared to 62 patients with idiopathic TMA, either with (45 patients, ADAMTS13 <5% idiopathic group) or without (17 patients, ADAMTS13 >or=5% idiopathic group) severe ADAMTS13 deficiency. ADAMTS13 <5% HIV(+) patients had less AIDS-related complications than ADAMTS13 >or=5% HIV(+) patients (23.5% versus 91.6%, respectively, P = 0.0005) and their median CD4(+) T cell count was higher (P = 0.05). TMA-associated death rate was higher in ADAMTS13 >or=5% HIV(+) patients than in ADAMTS13 <5% HIV(+) patients (50% versus 11.7%, respectively, P = 0.04). In ADAMTS13 <5% patients, TMA-associated death rate was comparable between HIV(+) and idiopathic patients (15.5% in idiopathic patients, P-value was non-significant). By contrast, TMA-associated death rate in ADAMTS13 >or=5% HIV(+) patients was higher than in idiopathic patients (11.7% in idiopathic patients, P = 0.04). In conclusion, HIV-associated TMA with severe ADAMTS13 deficiency have less AIDS-related complications and a higher CD4(+) T cell count. TMA prognosis is better and comparable to this of idiopathic forms.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1365-3083
|
| pubmed:author |
pubmed-author:AdrieCC,
pubmed-author:AzoulayEE,
pubmed-author:BoulangerEE,
pubmed-author:BusselAA,
pubmed-author:CoppoPP,
pubmed-author:DevauxEE,
pubmed-author:EschwègeVV,
pubmed-author:GalicierLL,
pubmed-author:GallienSS,
pubmed-author:KorachJ-MJM,
pubmed-author:MalakSS,
pubmed-author:MalotSS,
pubmed-author:MariottiAA,
pubmed-author:MeynardJ-LJL,
pubmed-author:MillotG AGA,
pubmed-author:Réseau d'Etude des Microangiopathies Thrombotiques (TMA-Rare Diseases...,
pubmed-author:RondeauEE,
pubmed-author:SchlemmerBB,
pubmed-author:VeyradierAA,
pubmed-author:WolfMM
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
68
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
337-44
|
| pubmed:meshHeading |
pubmed-meshheading:18782260-ADAM Proteins,
pubmed-meshheading:18782260-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:18782260-Adult,
pubmed-meshheading:18782260-CD4 Lymphocyte Count,
pubmed-meshheading:18782260-Case-Control Studies,
pubmed-meshheading:18782260-Death,
pubmed-meshheading:18782260-Female,
pubmed-meshheading:18782260-France,
pubmed-meshheading:18782260-HIV,
pubmed-meshheading:18782260-Humans,
pubmed-meshheading:18782260-Male,
pubmed-meshheading:18782260-Middle Aged,
pubmed-meshheading:18782260-Prognosis,
pubmed-meshheading:18782260-Prospective Studies,
pubmed-meshheading:18782260-Purpura, Thrombotic Thrombocytopenic,
pubmed-meshheading:18782260-von Willebrand Factor
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity.
|
| pubmed:affiliation |
Service d'Hématologie et de Thérapie Cellulaire, AP-HP, Hôpital Saint-Antoine and UPMC Université Paris 06, Paris, France.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|